{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:08:54Z","timestamp":1789711734173,"version":"4.0.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Xeligekimab, a monoclonal antibody targeting interleukin-17A (\n                      <jats:italic>IL-17A<\/jats:italic>\n                      ), has demonstrated high efficacy in treating moderate-to-severe plaque psoriasis. However, the detailed response patterns across anatomical regions, treatment targets, and patient-reported outcomes remain incompletely elucidated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis of a phase 3, randomized, double-blind, placebo-controlled trial (CHICTR2100043223) included 420 Chinese patients randomized 2:1 to receive subcutaneous xeligekimab 200 mg every 2 weeks or placebo for 12 weeks, followed by open-label xeligekimab through week 52. Regional Psoriasis Area and Severity Index (PASI) responses across four anatomical sites, treatment targets [ideal target: PASI 90 or absolute PASI \u22643 or body surface area (BSA) \u22641% or Physician\u2019s Global Assessment (PGA) 0\/1; acceptable target: PASI 75 or absolute PASI \u22645 or BSA \u22643% or PGA 0\/1\/2; sustained remission: BSA\u00a0=\u00a00% or PGA\u00a0=\u00a00 for \u22656 months], and Dermatology Life Quality Index (DLQI) domain-specific improvements were comprehensively analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Xeligekimab produced rapid improvements across all PASI dimensions by week 4, with induration (\u221260.1%), scaling (\u221261.9%), and erythema (\u221250.3%) versus \u22125.3% to \u22127.7% for placebo (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). By week 12, reductions reached \u221291.1%, \u221290.9%, and \u221282.3%, respectively. Regional analysis showed that head lesions responded most rapidly (PASI 90: 84.2% at week 12), with week 52 regional PASI 90 rates ranging from 81.2% to 92.1%. Ideal and acceptable target achievement rates reached 86.6% and 94.9% at week 12 versus 4.6% and 9.9% for placebo (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), increasing to 91.0% and 98.0% by week 52. The median time to sustained remission was 48 weeks for xeligekimab. By weeks 52 and 60, sustained remission rates reached 50.1% and 54.1%, respectively. Patient-reported outcomes demonstrated rapid and comprehensive improvement across all DLQI functional dimensions by week 4, with low-impact rates exceeding 90% by week 12 for physical symptoms (97.0% for symptoms, 92.0% for pruritus), psychological burden (98.0%), daily activities (97.1%\u201398.2%), social functioning (98.0%), work\/study (97.0%), and treatment burden (99.0%), all significantly superior to placebo (all\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Xeligekimab provides rapid symptom resolution across all clinical dimensions, high and sustained achievement of treatment targets, and comprehensive restoration of quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn<\/jats:ext-link>\n                      , identifier CHICTR2100043223.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1917350","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:49Z","timestamp":1789709809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Kun","family":"Huang","sequence":"first","affiliation":[{"name":"Dermatology Department, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Dermatology Department, Beijing Tsinghua Changgung Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Dermatology Department, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.36849\/jdd.5821","article-title":"Effect of Ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies","volume":"20","author":"Gooderham","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17128","article-title":"Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management","volume":"179","author":"Augustin","year":"2018","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2102383","article-title":"Bimekizumab versus Secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"191","author":"Cai","year":"2024","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/ptt.s312109","article-title":"Effectiveness of IL-23 inhibitor Guselkumab in real-world Chinese patients with psoriasis during a 20-week period","volume":"11","author":"Chan","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.35541\/cjd.20220652","article-title":"Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents","volume":"56","year":"2023","journal-title":"Chin J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1625","article-title":"Defining on-treatment remission in plaque psoriasis: a consensus statement from the National Psoriasis Foundation","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17403","article-title":"Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients","volume":"181","author":"Augustin","year":"2019","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15950","article-title":"Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: a real-world retrospective study and literature review","volume":"35","author":"Cheng","year":"2022","journal-title":"Dermatol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011535.pub4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","article-title":"Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"99","author":"Tada","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14951","article-title":"Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study","volume":"80","author":"Paul","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of Ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1503824","article-title":"Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.013","article-title":"Research techniques made simple: murine models of human psoriasis","volume":"138","author":"Hawkes","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman","year":"2016","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:49Z","timestamp":1789709809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1917350"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1917350","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1917350"}}